In heart failure, the Kansas City Cardiomyopathy Questionnaire (KCCQ) has been qualified by the U.S. Food and Drug Administration as a Clinical Outcome Assessment and recommended as …

Kansas City Cardiomyopathy Questionnaire (KCCQ-12) The following questions refer to your heart failure and how it may affect your life. Please read and complete the following questions. …

2020年4月9日 · This qualification statement supports the KCCQ-23 Total Symptom Score, Physical Limitations Score and Clinical Summary Score as measures of their respective …

2020年11月17日 · In heart failure, the Kansas City Cardiomyopathy Questionnaire (KCCQ) has been qualified by the U.S. Food and Drug Administration as a Clinical Outcome Assessment …

2020年11月17日 · This review describes how to interpret the KCCQ, how it should be analyzed in clinical trials to maximize the interpretability of results, and how it can be used in clinical …

The Clinical Summary Score (CSS) of the Kansas City Cardiomyopathy Questionnaire (KCCQ), a patient-reported outcome instrument, provides a measure of symptoms and physical …

In April 2020, the U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) approved the use of the Kansas City Cardiomyopathy Questionnaire …

The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a new, self-administered, 23-item questionnaire that quantifies physical limitations, symptoms, self-efficacy, social interference …

2020年11月1日 · In heart failure, the Kansas City Cardiomyopathy Questionnaire (KCCQ) has been qualified by the U.S. Food and Drug Administration as a Clinical Outcome Assessment …

Background—Improving functional status and quality of life are important goals of treatment for patients with severe aortic stenosis. The Kansas City Cardiomyopathy Questionnaire (KCCQ) …